RT @DiabetologiaJnl: A review of SGLT inhibitor adjunct therapy in type 1 diabetes #T1D #type1diabetes #insulintherapy https://t.co/MawNkCO…
RT @DiabetologiaJnl: A review of SGLT inhibitor adjunct therapy in type 1 diabetes #T1D #type1diabetes #insulintherapy https://t.co/MawNkCO…
RT @DiabetologiaJnl: A review of SGLT inhibitor adjunct therapy in type 1 diabetes #T1D #type1diabetes #insulintherapy https://t.co/MawNkCO…
RT @DiabetologiaJnl: A review of SGLT inhibitor adjunct therapy in type 1 diabetes #T1D #type1diabetes #insulintherapy https://t.co/MawNkCO…
SGLT2i in T1DM DEPICT-1 and Tandem confer additional benefits in terms of a 5–6 mmol/mol (0.4–0.5%) reduction in HbA1c accompanied by weight loss and reductions in total daily insulin doses. Not increase hypoglycemia, but ketoacidosis.
A review of SGLT inhibitor adjunct therapy in type 1 diabetes #T1D #type1diabetes #insulintherapy https://t.co/MawNkCOX30
RT @DiabetologiaJnl: A review of SGLT inhibitor adjunct therapy in type 1 diabetes #T1D #SGLTinhibitor #insulintherapy https://t.co/MawNkD6…
A review of SGLT inhibitor adjunct therapy in type 1 diabetes #T1D #SGLTinhibitor #insulintherapy https://t.co/MawNkD6yrA
RT @CristobMorales: https://t.co/N3yfBDGheR SGLT inhibitor adjunct therapy in type 1 diabetes @DiabetologiaJnl @SEDiabetes https://t.co/ki…
RT @CristobMorales: https://t.co/N3yfBDGheR SGLT inhibitor adjunct therapy in type 1 diabetes @DiabetologiaJnl @SEDiabetes https://t.co/ki…
https://t.co/N3yfBDGheR SGLT inhibitor adjunct therapy in type 1 diabetes @DiabetologiaJnl @SEDiabetes https://t.co/kiQMnYyfRQ
RT @drpratikc: Gr8 review on SGLT2 in T1 @ABCDiab @DTN_UK @youngdiab https://t.co/23Abd4IO8A
Still waiting for Low empa dose results 😘😘
RT @drpratikc: Gr8 review on SGLT2 in T1 @ABCDiab @DTN_UK @youngdiab https://t.co/23Abd4IO8A
RT @drpratikc: Gr8 review on SGLT2 in T1 @ABCDiab @DTN_UK @youngdiab https://t.co/23Abd4IO8A
RT @drpratikc: Gr8 review on SGLT2 in T1 @ABCDiab @DTN_UK @youngdiab https://t.co/23Abd4IO8A
A recent hot discussion topic at our departmental meeting.
RT @drpratikc: Gr8 review on SGLT2 in T1 @ABCDiab @DTN_UK @youngdiab https://t.co/23Abd4IO8A
RT @drpratikc: Gr8 review on SGLT2 in T1 @ABCDiab @DTN_UK @youngdiab https://t.co/23Abd4IO8A
RT @drpratikc: Gr8 review on SGLT2 in T1 @ABCDiab @DTN_UK @youngdiab https://t.co/23Abd4IO8A
RT @drpratikc: Gr8 review on SGLT2 in T1 @ABCDiab @DTN_UK @youngdiab https://t.co/23Abd4IO8A
RT @drpratikc: Gr8 review on SGLT2 in T1 @ABCDiab @DTN_UK @youngdiab https://t.co/23Abd4IO8A
“results suggest that SGLT inhibition will have a place in the management of T1D...use of SGLTi in routine T1D care will require specific patient and healthcare professional educational packages to ensure patient safety and to minimise risk.” https://t.co
Gr8 review on SGLT2 in T1 @ABCDiab @DTN_UK @youngdiab https://t.co/23Abd4IO8A
RT @drjamesboyle: Lovely synthesis of the literature as well as really useful recommendations for the use of #SGLT2 inhibitors as adjunct t…
And I was wondering what I was going to read on a Sunday morning alongside my coffee :--)
Lovely synthesis of the literature as well as really useful recommendations for the use of #SGLT2 inhibitors as adjunct therapy in #T1DM in @DiabetologiaJnl by @UoDMedicine Rory McCrimmon & @UCSanDiego Robert Henry: https://t.co/K5DMjq9Vm9 https://t.co